The Mintaka Foundation for Medical Research in Geneva announced today that the Wellcome Trust, London, has awarded it approximately CHF 4,500,000 to meet the remaining costs of bringing its flagship product, an anti-HIV microbicide known as 5P12-RANTES, to a first safety trial in the clinic. Every year, there are millions of new infections from HIV. More than 95% of these occur in the developing world, and over half of these are women and young girls. For many reasons few are protected by condom use...
More...
More...